IFLR1000

Pfizer $11.4 billion acquisition of Array BioPharma

17/6/2019
Public acquisition
Select tab

$ 11.4 billion

Announced

17/6/2019

Overview:

  • Pfizer has acquired Array BioPharma in an $11.4 billion deal. 
  • Array develops small molecule medicines, including for cancer treatments. 
  • Guggenheim Securities and Morgan Stanley acted as financial advisers for Pfizer and Centerview Partners advised Array. 
  • The transaction is expected to close in the second half of 2019. 

Kurt Stumpo - US Editor

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:
Debevoise & Plimpton

Party: Guggenheim Securities (Financial adviser)

Party: Morgan Stanley (Financial adviser)

Lawyer: Andrew Bab

Skadden Arps Slate Meagher & Flom

Party: Array Biopharma (Target)

Wachtell Lipton Rosen & Katz

Party: Pfizer (Acquirer)

Lawyers: Brandon Price, Edward Herlihy

Related deals